Potential markers that complement expression of CA125 in epithelial ovarian cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hoskins, 1995, Prospective on ovarian cancer: why prevent?, J. Cell Biochem., Suppl., 23, 189, 10.1002/jcb.240590926
Bourne, 1993, Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging, Br. Med. J., 306, 1025, 10.1136/bmj.306.6884.1025
Van Nagell, 2000, The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer, Gynecol. Oncol., 77, 350, 10.1006/gyno.2000.5816
Sato, 2000, Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography, Cancer, 89, 585, 10.1002/1097-0142(20000801)89:3<582::AID-CNCR13>3.0.CO;2-#
Bast, 1985, Elevation of serum CA125 prior to diagnosis of an epithelial ovarian carcinoma, Gynecol. Oncol., 22, 115, 10.1016/0090-8258(85)90015-0
Einhorn, 1992, Prospective evaluation of serum CA125 levels for early detection of ovarian cancer, Obstet. Gynecol., 80, 14
Jacobs, 1996, Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: a prospective cohort study, Br. Med. J., 313, 1355, 10.1136/bmj.313.7069.1355
Jacobs, 1999, Multimodal approach to screening for ovarian cancer, Lancet, 268
Rosenthal, 1998, The role of CA125 in screening for ovarian cancer, Int. J. Biol. Makers, 13, 651
Urban, 1997, Use of a stochastic simulation model to identify and efficient protocol for ovarian cancer screening, Control. Clin. Trials, 18, 251, 10.1016/S0197-2456(96)00233-4
Skates, 1995, Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers, Cancer, 76, 2004, 10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G
Skates, 2003, Calculation of the risk of ovarian cancer from serial CA125 values for preclinical detection in postmenopausal women, J. Clin. Oncol., 21, 206, 10.1200/JCO.2003.02.955
Lu, 2004, Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis, Clin. Cancer Res., 10, 3291, 10.1158/1078-0432.CCR-03-0409
Bast, 2002, Early detection of ovarian cancer: promise and reality, 61
Scully, 1975, World health organization classification and nomenclature of ovarian cancer, Natl. Cancer Inst. Monogr., 42, 5
Shepard, 1989, Revised FIGO staging for gynaecological cancer, BR. J. Obstet. Gynaecol., 96, 889, 10.1111/j.1471-0528.1989.tb03341.x
Nap, 1996, Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop, Tumour Biol., 17, 325, 10.1159/000217996
Diamandis, 2002, Human tissue kallikreins: a family of new cancer biomarkers, Clin. Chem., 48, 1198, 10.1093/clinchem/48.8.1198
Ichige, 1995, Expression of the DF3-P epitope in human ovarian carcinomas, Clin. Cancer Res., 1, 565
Dong, 1997, Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours, J. Pathol., 183, 311, 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2
Li, 2004, Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer, Anticancer Res., 24, 1973
Breitenecker, 1989, Comparison between tissue and serum content of CA125, CA19-19 and carcinoembryonic antigen in ovarian tumors, Int. J. Gynecol. Pathol., 8, 97, 10.1097/00004347-198906000-00002
Hellstrom, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res., 63, 3695
Kim, 2002, Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA, 287, 1671, 10.1001/jama.287.13.1671
McIntosh, 2004, Combining CA125 and SMR serum markers for diagnosis and detection of ovarian carcinoma, Gynecol. Oncol., 95, 9, 10.1016/j.ygyno.2004.07.039
Rosen, 2004, Validation of tissue microarray technology in ovarian carcinoma, Mod. Pathol., 10.1038/modpathol.3800120
Jacobs, 1989, CA125 tumour-associated antigen: a review of the literature, Hum. Reprod., 4, 1, 10.1093/oxfordjournals.humrep.a136832
Chang, 1996, Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers, Proc. Natl. Acad. Sci. U. S. A., 93, 134, 10.1073/pnas.93.1.136
Wang, 1999, Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray, Gene, 229, 101, 10.1016/S0378-1119(99)00035-9
Scholler, 1999, Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma, Proc. Natl. Acad. Sci. U. S. A., 96, 11531, 10.1073/pnas.96.20.11531
Borgono, 2004, The emerging roles of human tissue kallikreins in cancer, Nat. Rev., Cancer, 4, 876, 10.1038/nrc1474
Shvartsman, 2003, Overexpression of kallikrein 10 in epithelial ovarian carcinomas, Gynecol. Oncol., 90, 44, 10.1016/S0090-8258(03)00257-9
Adib, 2004, Predicting biomarkers for ovarian cancer using gene-express microarrays, Br. J. Cancer, 90, 686, 10.1038/sj.bjc.6601603
Santin, 2004, Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy, Int. J. Cancer, 112, 14, 10.1002/ijc.20408
Hibbs, 2004, Differential gene expression in ovarian carcinoma. Identification of potential biomarkers, Am. J. Pathol., 165, 397, 10.1016/S0002-9440(10)63306-8
Diamandis, 2003, Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma, J. Clin. Oncol., 21, 1035, 10.1200/JCO.2003.02.022
Luo, 2003, The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis, Cancer Res., 63, 807
Tuck, 1997, Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas, Arch. Pathol. Lab. Med., 121, 578
Chambers, 1996, Osteopontin expression in lung cancer, Lung Cancer, 15, 311, 10.1016/0169-5002(95)00595-1
Thalmann, 1999, Osteopontin: possible role in prostate cancer progression, Clin. Cancer Res., 5, 2271
Agrawal, 2002, Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling, J. Natl. Cancer Inst., 94, 513, 10.1093/jnci/94.7.513
Tuck, 2001, The role of osteopontin in breast cancer: clinical and experimental studies, J. Mammary Gland Biol. Neoplasia, 6, 419, 10.1023/A:1014734930781
Furger, 2001, The functional and clinical roles of osteopontin in cancer and metastasis, Curr. Mol. Med., 1, 621, 10.2174/1566524013363339
Giachelli, 2000, Osteopontin: a versatile regulator of inflammation and biomineralization, Matrix Biol., 19, 615, 10.1016/S0945-053X(00)00108-6
Reinholt, 1990, Osteopontin—A possible anchor of osteoclasts to bone, Proc. Natl. Acad. Sci. U. S. A., 87, 4473, 10.1073/pnas.87.12.4473
Patarca, 1993, Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene, Crit. Rev. Immunol., 13, 224
Shijubo, 2000, Vascular endothelial growth factor and osteopontin in tumor biology, Crit. Rev. Oncog., 11, 135
Brakora, 2004, Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer, Gynecol. Oncol., 93, 361.5, 10.1016/j.ygyno.2004.01.050
Tsukita, 2001, Multifunctional strands in tight junctions, Nat. Rev., Mol. Cell Biol., 2, 285, 10.1038/35067088
Rangel, 2003, Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas, Clin. Cancer Res., 9, 2567
Sekine, 1985, Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma, J. Clin. Oncol., 3, 1355, 10.1200/JCO.1985.3.10.1355
Croce, 2003, Tissue and serum MUC1 mucin detection in breast cancer patients, Breast Cancer Res. Treat., 81, 195, 10.1023/A:1026110417294
Rahn, 2001, The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature, Cancer, 91, 1973, 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A
Feng, 2002, Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas, Jpn. J. Clin. Oncol., 32, 525, 10.1093/jjco/hyf111
Harlozinska, 2004, Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma, Anticancer Res., 24, 1149
Demirkiran, 2003, Vascular endothelial growth factor in adnexal masses, Int. J. Gynaecol. Obstet., 83, 53, 10.1016/S0020-7292(03)00208-X
Tempfer, 1998, Vascular endothelial growth factor serum concentrations in ovarian cancer, Obstet. Gynecol., 92, 360, 10.1016/S0029-7844(98)00190-2
Chen, 1999, Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival, Gynecol. Oncol., 74, 235, 10.1006/gyno.1999.5418
Gadducci, 1999, Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome, Anticancer Res., 19, 1401
Brown, 2000, Angiogenesis in ovarian cancer, Bailliere's Best. Pract. Res. Clin. Obstet. Gynaecol., 14, 901, 10.1053/beog.2000.0134
Skates, 2004, Pre-operative sensitivity and specificity for early stage ovarian cancer when combining CA125, CA 15.3, CA 72.4 and M-CSF using mixtures of multivariate normal distributions, J. Clin. Oncol., 22, 4059, 10.1200/JCO.2004.03.091
Zhang Z., Xu F.-J., Yu Y., Berchuck A., L. Havrilesky, de Bruijn H.W., van der Zee A., Woolas R.P., Jacobs I.J., Skates S., Bast Jr. R.C. Detection of stage I epithelial ovarian cancer using an artificial neural network derived composite index of multiple serum markers. Clin. Cancer Res. [In revision].